Paullee
6 년 전
AngioDynamics Seeks Biolitec Patents To Satisfy $75M Award
Share us on: By Sean Forbes
Law360 (June 19, 2018, 9:11 PM EDT) -- Medical technology company AngioDynamics Inc. hit Biolitec AG and its fugitive owner with a lawsuit in Massachusetts federal court seeking to gain control of the company’s patents to satisfy a nearly $75 million judgment that Biolitec has dodged for over four years.
New York-based AngioDynamics’ complaint is a new front in its long-running bid to collect on a judgment issued after Biolitec Inc. breached a deal requiring it to defend AngioDynamics from patent suits resulting from distribution of Biolitec’s laser ablation devices.
AngioDynamics expressed little expectation that Biolitec AG’s CEO Wolfgang Neuberger will pay the judgment, saying that he’s repeatedly drawn remonstrations from the court for dodging monetary responsibilities, and that he and his companies owe $70 million in civil contempt fines. AngioDynamics is instead seeking to be paid in patents that cover everything from treatments for varicose veins, ulcers, Barrett’s syndrome and oral diseases in cats, according to the complaint.
“The judgment debtors have refused to pay a penny of this court’s judgment,” AngioDynamics said, adding later, “The court should order an independent appraisal of the U.S. intellectual property nominally held by [Biolitec entities] and then order [them] to assign that property to AngioDynamics, crediting the appraised value of the property against the unsatisfied $74.9 million judgment.”
AngioDynamics originally hit Biolitec Inc. — the American arm of Neuberger’s corporate holdings — with a suit in January 2008 in New York federal court, alleging the company had breached a supply and distribution contract under which it was required to defend and indemnify AngioDynamics against infringement claims. AngioDynamics said two companies sued it for patent infringement over the Biolitec laser ablation technology, and that Biolitec refused to defend it or compensate it for millions of dollars in settlements and legal fees.
AngioDynamics won its first court battle against Neuberger in October 2012, when a New York federal judge ordered Biolitec Inc. to hand over $16.5 million for failing to shield its business partner from the IP litigation.
But in January 2013, with a $23 million final judgment still outstanding, Biolitec Inc. filed for bankruptcy and the company’s trustee entered into a settlement under which AngioDynamics agreed to forego its efforts to get the payout and to pursue Biolitec’s German parent company, Biolitec AG, Biomed Technology Holdings Inc. and Neuberger, all closely related to Biolitec Inc.
In March 2014, a Massachusetts federal court slapped Biolitec AG and its affiliates with the $74.9 million judgment, trebling the $23 million judgment under a Massachusetts consumer protection law and tacking on millions more in interest and attorneys’ fees.
Since then, Biolitec AG has refused to pay the judgment order as well as a $70 million civil contempt order, while Neuberger has been a fugitive from a court-issued arrest warrant, Monday’s suit says.
Biolitec AG and its affiliates have also refused to comply with postjudgment discovery orders about ownership and control of the intellectual property imposed in March, racking up $25,000 in sanctions each month it doesn’t produce evidence, the complaint says.
“In sum, despite repeated attempts and multiple orders by this court, the judgment debtors have provided no substantive discovery to AngioDynamics for over five years,” the company said.
AngioDynamics said Monday that despite Biolitec’s “contumacious refusal to provide court-ordered discovery” about U.S.-based intellectual property it owns, it had identified dozens of patents owned by the company.
The complaint further argues that Neuberger has flouted the rules requiring corporations to be kept separate, and has “pervasive control” over all of the Biolitec group of companies, including Austria-based Biolitec AG and Biolitec Unternehmensbeteiligungs II AG, Malaysia-based Biomed Technology Holdings Ltd. and Biolitec Pharma Marketing Ltd., and Latvia-based Biolitec SIA.
AngioDynamics says that Neuberger has shifted business assets between entities and capitalized entities as it has suited his personal interests, ignored corporate formalities, failed to keep corporate records and siphoned funds and assets for his own use, among a host of other claims.
AngioDynamics urged the court in Monday’s complaint to issue an order directing an appraisal of the fair market value of the Biolitec-linked U.S. intellectual property it has identified, and directing Neuberger to transfer the patents to AngioDynamics. If Neuberger refuses to transfer the IP, then the court should issue an order directly handing them over to AngioDynamics, according to the complaint.
AngioDynamics is also seeking injunctive relief to prevent Neuberger and his companies from transferring ownership of the intellectual property to other parties, a declaration that Neuberger’s companies are related and alter egos of each other, and a determination that they are jointly and separately liable for the $75 million judgment, according to the complaint.
Counsel for AngioDynamics did not immediately respond to a request for comment. Biolitec AG and Biomed Technology Holdings Ltd. did not immediately respond to requests for comment.
AngioDynamics is represented by William E. Reynolds of Nixon Peabody LLP.
Counsel information for Biolitec AG was not immediately available.
The case is AngioDynamics Inc. v. Neuberger et al., case number 3:18-cv-30092, in the U.S. District Court for the Western District of Massachusetts.
--Additional reporting by Dani Kass. Editing by Breda Lund.
Paullee
7 년 전
AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer
Business Wire Business WireJanuary 24, 2018
LATHAM, N.Y.--(BUSINESS WIRE)--
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted the Expedited Access Pathway (EAP) designation to the Company’s NanoKnife® System and proposed indication for use for the treatment of Stage III pancreatic cancer.
The EAP program is designed to help patients gain more timely access to medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, for which no approved or cleared alternatives exist. This is achieved by expediting the device’s assessment and review processes through more interactive and timely communication with the FDA, pre- and post-market balance of data collection requirements, efficient and flexible clinical study design, FDA review team support and Agency senior management engagement, and priority review.
Pursuant to the recently enacted 21st Century Cures Act, the FDA has released draft guidance for a Breakthrough Devices Program, which, when finalized, will supersede the EAP. The FDA has indicated that all devices that receive EAP designation will gain Breakthrough Device designation when the guidance document becomes final.
Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc., commented, “The Expedited Access Pathway and Breakthrough Devices Program is an important and meaningful initiative to prioritize review and approval for novel, innovative devices needed by patients for the treatment of life-threatening diseases and conditions. We are thrilled that the FDA has granted the EAP designation to NanoKnife for the treatment of Stage III pancreatic cancer and are excited to continue working with the FDA toward approval of NanoKnife as a treatment for the underserved patient population suffering from this deadly disease.”
Paullee
8 년 전
Bard Hit With Antitrust Suit Over Alleged Catheter Tying
By Rachel Graf
Law360, New York (June 1, 2017, 4:24 PM EDT) -- Medical technologies manufacturer C.R. Bard Inc. has unlawfully tied its popular tip location systems to its peripherally inserted central catheters in order to drive sales of its own PICCs at the expense of competitors, according to a suit filed by AngioDynamics Inc. Tuesday in New York federal court.
AngioDynamics said Bard only sells the stylet needed to use its tip location systems preloaded in its PICCs, violating antitrust laws and hurting sales of AngioDynamics’ own BioFlo PICCs that purportedly use superior technology to reduce blood clots. The tip location systems help doctors correctly position PICCs in patients.
“Even though AngioDynamics’ groundbreaking BioFlo PICCs significantly reduce thrombus accumulation and the reflux of blood, and are thus technologically far superior to Bard’s PICCs, Bard’s anti-competitive conduct has allowed it to capture and maintain a dominant position in the PICC market, exceeding 70 percent market share,” AngioDynamics said in the filing.
AngioDynamics’ BioFlo PICCs use Endexo Technology that reduces blood clots and consequently diminishes the likelihood of blood clotting events such as deep vein thrombosis and pulmonary embolism, according to the complaint.
Bard has been unable to create a PICC that can effectively reduce blood clots, but its tip location systems are very popular and make up more than 70 percent of the market, AngioDynamics claims.
Bard has leveraged this dominance in the tip location systems market to block PICC competition by tying the two products together, negatively impacting PICC price competition and making it difficult for AngioDynamics to grow its business, the filing said.
“We strongly deny the allegations raised by AngioDynamics in their complaint,” Scott Lowry, Bard vice president and treasurer, said in an emailed statement. “Clinicians select Bard products based on the clinical and economic benefits they provide to patients and health care providers. We intend to vigorously defend those claims.”
Bard’s decision to tie its tip location systems to its PICCs is motivated by purely competitive rather than technological reasons, the complaint claims. AngioDynamics notes that Bard did in fact receive FDA approval to sell its stylet separately from its PICCs, but has sold the stylet separately only to the Cleveland Clinic, which was then able to pair Bard’s tip location system with AngioDynamics’ BioFlo PICCs.
AngioDynamics is alleging violation of the Sherman Act and is seeking damages, an injunction, and attorneys’ fees and costs.
"This case involves a classic violation of the antitrust laws. Bard has no justification for preventing purchasers from choosing to use its market-leading tip location systems with AngioDynamics' innovative BioFlo PICCs," Philip J. Iovieno of Boies Schiller Flexner, counsel for AngioDynamics, said in a statement.
AngioDynamics is represented by Philip J. Iovieno, Adam R. Shaw, Anne M. Nardacci, Jenna C. Smith and Nicholas A. Gravante Jr. of Boies Schiller Flexner LLP.
Counsel information for Bard was not available Thursday.
The suit is AngioDynamics Inc. vs. C.R. Bard Inc., Bard Access Systems, Inc., case number 1:17-cv-00598 in the U.S. District Court for the Northern District of New York.
--Editing by Philip Shea.
Paullee
8 년 전
COLONIE — Latham's AngioDynamics is alleging that a major competitor in the medical device market, C.R. Bard, is violating anti-trust laws in the sale of its catheters.
In a lawsuit filed in U.S. District Court in Albany, AngioDynamics claims that C.R. Bard's practice of pre-loading its catheter tip placement devices with its own catheters harms competition in the market since it doesn't allow its customers the ability to use catheters made by other companies such as AngioDynamics.
The so-called tip placement devices use imaging technology to locate the correct spot on the body to insert the catheter, which is typically used to administer drugs to a patient directly into their blood stream.
C.R. Bard pre-loads its own catheters into the handheld stylet used with the device. AngioDynamics wants the court to force C.R. Bard to stop this practice of pre-loading its catheters into its stylets, arguing it forces hospitals and doctors into using C.R. Bard catheters. AngioDynamics does not make its own tip placement devices, while those sold by C.R. Bard are some of the most popular on the market.
AngioDynamics says C.R. Bard's practice of pre-loading the catheters into its tip placement devices contributes to high healthcare costs because AngioDynamics' catheters have been shown to lead to fewer complications from improper insertion, which reduces patient costs.
"We are committed to fighting Bard's illegal scheme that has been detrimental to patients, reduced competition and led to increased cost in the marketplace," said AngioDynamics CEO Jim Clemmer.
AngioDynamics, which had $353 million in sales during its fiscal 2016, has 1,300 employees. It's headquarters is in Latham, but it has large distribution and manufacturing operations in Glens Falls and Queensbury. Other locations are in Georgia and outside of Boston. It also has two overseas facilities.
AngioDynamics is seeking undisclosed damages that it has suffered from C.R. Bard's practices, although catheters aren't always inserted into patients using a tip-placement device. The company is being represented by the law firm of Boies Schiller Flexner LLP, including two attorneys in its Albany office, Philip Iovieno and Anne Nardacci.
"This case involves a classic violation of the antitrust laws. Bard has no justification for preventing purchasers from choosing to use its market-leading tip location systems with AngioDynamics' innovative BioFlo PICCs," Iovieno said.
C.R. Bard officials in New Jersey did not immediately have a response to the lawsuit when contacted Wednesday morning. C.R. Bard and AngioDynamics have a history of litigation against one another, with C.R. Bard alleging patent violations against AngioDynamics in lawsuits in recent years.
starbuxsux
11 년 전
Press Release: AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
4:01 PM ET 10/10/13 | Dow Jones
AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
-- Net sales of $83.6 million
-- GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04
per share; Non-GAAP adjusted net income excluding amortization of $0.12
per share
-- Adjusted EBITDA of $11.3 million
-- Operating cash flow of $7.3 million versus prior year $5.6 million cash
use
-- Company raises FY 2014 guidance for revenue and adjusted EPS excluding
amortization
ALBANY, N.Y., Oct. 10, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the fiscal 2014 first quarter ended August 31, 2013.
"Our growth drivers performed at, or above, our expectations in the first quarter, demonstrating the value in our strategic initiatives and ability to expand market opportunities for our products," said Joseph M. DeVivo, President and Chief Executive Office. "Our sales team is approaching the market with solutions, including our AngioVac cannula and circuit, and growing BioFlo portfolio, that are valued by the healthcare industry not only for their potential to improve patient outcomes, but also for reducing overall treatment costs. Early data following the commercialization of our BioFlo PICCs has shown the capability to dramatically reduce PICC-related upper extremity deep vein thrombosis -- a problem that is estimated to cost hospitals more than $1 billion annually. The market's response and product results are encouraging, and coupled with other positive developments, supports our expectation of accelerated growth commencing in the fiscal 2014 second half."
Q1 FY14 Financial Results
Net sales of $83.6 million were flat with last year's first quarter net sales of $83.4 million. Excluding the planned wind down of the supply agreement with Boston Scientific, sales in the quarter grew by 1% compared to the prior year period.
Peripheral Vascular net sales in the first quarter increased 5% to $45.5 million compared to $43.2 million in the prior year period. Vascular Access net sales declined 5% to $25.3 million compared to $26.6 million in the year ago quarter. Oncology/Surgery net sales of $11.2 million were similar to the year ago quarter. Supply agreement sales of $1.6 million in this fiscal year's first quarter declined from $2.3 million in the prior year period.
Net sales in the U.S., excluding the supply agreement, increased 2% to $67.1 million from $65.6 million in the prior year period. International net sales decreased 5% to $14.8 million from $15.6 million a year ago.
The Company's net loss in the first quarter was $0.4 million, or $0.01 per share, compared to a net loss of $0.7 million, or $0.02 per share, a year ago. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $1.3 million, or $0.04 per share, compared to $3.5 million, or $0.10 per share, a year ago. Excluding amortization, the Company's adjusted EPS was $0.12 for the first quarter of fiscal year 2014 compared to $0.16 for the year ago quarter. Current year results include a $0.02 impact of the Medical Device Tax, which was not applicable in the prior year period.
First quarter EBITDA grew to $7.4 million, or $0.21 per share, compared to EBITDA of $6.6 million, or $0.19 per share, a year ago. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $11.3 million, or $0.32 per share, compared to $14.3 million, or $0.41 per share, in the year ago period.
During the first quarter, operating cash flow improved to $7.3 million compared to $5.6 million of net cash used in the prior year quarter. At August 31, 2013, cash and investments were $24 million, and debt was $142.5 million. On September 24, 2013, the Company announced that it amended its existing credit facilities and successfully refinanced its long-term debt. This will improve the Company's capital structure by reducing interest expense by over $1 million per year, increasing the Company's future cash flow and providing greater flexibility to support the execution of its growth strategy.
Recent Operational Highlights
-- The U.S. Food and Drug Administration granted 510(k) clearance for the
Company's BioFlo port with Endexo technology which is designed to reduce
the accumulation of catheter-related thrombus on, and in, the port
catheter. Additionally, the Company expanded its agreement with Interface
Biologics, the creator of the Endexo technology in AngioDynamics' BioFlo
devices, to include central venous catheters.
-- The Company signed a sole-source, three-year agreement with the Large
Integrated Delivery Network Group (LIDN) -- a group formed by eight IDNs
from large Premier, Inc. member healthcare systems. Under the terms of
the agreement, effective November 1, 2013, AngioDynamics' entire port
line, including its new BioFlo ports, will be available to approximately
130 hospitals in the group. AngioDynamics continues to build on its
GPO/IDN strategy, bolstered by the success of its BioFlo platform, which
was recently showcased at the Novation Innovation Technology Expo and
MedAsset's 2013 Technology and Innovation forum.
-- The first patient was enrolled at Academic Medical Center, Amsterdam, the
Netherlands, by the Clinical Research Office of the Endourological
Society (CROES) in an investigator-led, multi-center study assessing the
safety, efficacy and patient satisfaction of the NanoKnife System for the
ablation of prostate cancer. Additionally, the first patient was enrolled
in the multi-center PICC Related Obstruction of Flow (PROOF) Study
investigating whether the BioFlo PICC will be associated with a reduced
incidence of catheter-related venous thrombosis compared to the Bard
PowerPICC SOLO2.
-- The National Institute for Health and Care Excellence (NICE) issued
updated guidance for the treatment of varicose veins. The newly issued
guidance establishes endothermal ablation, which includes endovascular
laser treatment like the Company's VenaCure EVLT system, as the
recommended first option in treating varicose veins.
-- The Company announced its distribution partner, Medcomp Inc., received
Health Canada approval for the Celerity tip location system.
AngioDynamics plans to initiate distribution of the Celerity system in
Canada this month. The system is currently under regulatory review in the
United States and Europe. The Company believes the combination of the
Celerity system with its market-leading, thrombus-resistant BioFlo
technology will provide unparalleled clinical and economic advantages,
and has the potential to become the gold standard in the PICC market.
-- The Company acquired privately-held Clinical Devices, B.V., to obtain the
global rights to a next-generation tip location technology currently
under development. As part of the transaction, AngioDynamics will also
acquire its Netherlands-based distributor of NAMIC fluid management
products.
Full Year and Second Quarter Fiscal 2014 Guidance
"We are raising revenue expectations, following the recent distributor acquisition, to a range of $347 million to $353 million. As a result of our debt refinance results, we also are increasing our adjusted EPS without amortization to be $0.63-$0.67," said Mark Frost, Executive Vice President and Chief Financial Officer. "We are anticipating revenue to range from $85 million to $88 million in the second quarter, up 1% on the top end. Adjusted EPS without amortization is expected to be $0.12-$0.15."
Conference Call
AngioDynamics will host a conference call today at 4:30 p.m. Eastern Time to discuss its first quarter results. To participate in the live call, please dial 1-877-941-8609. In addition, a live webcast and archived replay of the call will be available at http://investors.angiodynamics.com. To access the live webcast, please go to the website 15 minutes prior to its start to register, download and install the necessary software.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA, adjusted net income and adjusted earnings per share excluding amortization. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
About AngioDynamics
(MORE TO FOLLOW) Dow Jones Newswires
October 10, 2013 16:01 ET (20:01 GMT)
starbuxsux
11 년 전
Hello $ANGO
AngioDynamics Signs Multi-Year, Sole-Source Agreement With Large Integrated Delivery Network Group
11:51 AM ET 10/10/13 | GlobeNewswire
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has signed a sole-source, three-year port product agreement with the Large Integrated Delivery Network Group (LIDN) - a group formed by eight IDNs from large Premier, Inc. member healthcare systems, including Adventist Health, Carolinas Healthcare System, Fairview Health System, Henry Ford Health System, Methodist Health System, Norton Healthcare, Park Nicollet, and Texas Health Resources, in order to transform supply chain services.
"The comprehensiveness of our Vascular Access product line following the Navilyst transaction has allowed us to execute a strategy focused on deeper penetration of GPOs and IDNs," said Joseph M. DeVivo, President and CEO of AngioDynamics. "The LIDN's choice of our ports illustrates the promise in this opportunity, demonstrating our ability to increase our patient and product volume by capitalizing on opportunities to gain momentum in the U.S."
Under the terms of the agreement, effective November 1, 2013, AngioDynamics' entire port line, including its new BioFlo Ports, will be available to approximately 130 hospitals in the group that utilize ports. Annually, LIDN Members accounts for approximately $3.8 billion in healthcare spend, with up to $4 million being spent specifically on implantable ports.
"We are pleased to bring value to the LIDN and its member companies by offering our quality port products, including our recently FDA-cleared BioFlo ports," said Scott Centea, AngioDynamics' Director of Corporate Accounts. "Featuring Endexo technology, BioFlo ports are designed to reduce the accumulation of catheter-related thrombus on, and in, the port catheter, highlighting the innovative technologies in our comprehensive port portfolio."
About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
Trademarks
AngioDynamics, the AngioDynamics logo, BioFlo and Navilyst are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Endexo is a trademark of Interface Biologics.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
View data
CONTACT: Company Contact: AngioDynamics, Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Michael Polyviou/Robert Jones (212) 850-6020; (646) 201-5447 mpolyviou@evcgroup.com; bjones@evcgroup.com Media Contact: EVC Group, Inc. Nicole Kruse (212) 850-6025 nkruse@evcgroup.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNTIxNDYjMTY5MTQ=
Penny Roger$
13 년 전
AngioDynamics, Inc. (AngioDynamics) is a provider of medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD) and local oncology therapy options for treating cancer, including radiofrequency ablation (RFA) systems, embolization products for treating benign and malignant tumors and surgical resection systems, including NanoKnife Ablation Systems. It designs, develops, manufactures and markets a line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases. The Company’s segments include Vascular segment, which is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets, and Oncology /Surgery segment, is responsible for radio frequency (RF) Ablation, embolization, Habib and NanoKnife product lines.
http://www.google.com/finance?q=ANGO
Hot Features
프리미엄
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
EarningsCentral
1 월 전
Monksdream
6 월 전
toxrednil
3 년 전
whytestocks
4 년 전
